Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Attendo confirms talks regarding a possible acquisition of certain business in Team Olivia

Attendo AB (publ) has noted the recent speculation in media and confirms that it is in discussions concerning a possible acquisition of certain business in Team Olivia. There can be no certainty that an acquisition will be made, nor as to the terms of any such acquisition. For further information, please contact: Andreas Koch, Communications and IR-Director Attendo Phone: +46 705 09 77 61   I   email: andreas.koch@attendo.com This is information that Attendo AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for

Curasight A/S submits clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients

· Company on track to dose first patient in 2Q 2024 · CTA marks progress in development of uTRACE[®] in prostate cancer under the collaboration between Curasight and Curium Copenhagen, December 18, 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) today announced submission of clinical trial application (CTA) to the European Medicines Agency (EMA) for the investigation of uTRACE® in a phase 2 trial as a non-invasive alternative or supplement to traditional biopsies in prostate cancer patients in active surveillance.The CTA was submitted under the new application

Buy-back of shares in Arise during week 50, 2023

During the period between 11 December and 15 December 2023 Arise AB (publ) (LEI code 549300FOT7EE85QYB655) (“Arise”) repurchased, in total, 130,212 own shares (ISIN code SE0002095604) under the share repurchase program initiated by the Board of Directors to deliver shareholder value and to optimize the capital structure of the company. The share buy-backs form a part of the share repurchase program of a maximum amount of SEK 100 million, which Arise announced on 14 November 2023. The share repurchase program, which runs from 16 November 2023 until the date of Arise's Annual General

Set-Off Issue Completed, triggering Mandatory Public Bid Rule (“Budpliktsregeln”) on Nasdaq First North

The Swedish Companies Registration Office (‘Bolagsverket’) has now approved the Set-Off Issue that Shareholders resolved to carry out at the EGM held in Stockholm on Friday 8 December 2023. As a result, Per Lindberg, who is the CEO, now owns 25,818,738 shares in Ranplan Group, corresponding to 54.80% of a total of 47,118,242 (each share represents one vote). The 30% threshold of all outstanding votes in the Company has thus been surpassed, entailing that the Mandatory Public Bid Rule (“Budpliktsregeln”) will come into effect. Per Lindberg will revert via a press release within the

#23-392 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

Inside information: Toivo Group Plc announces its intention to carry out a directed share issue of new shares

Toivo Group Oyj – Company release Inside information 18 December 2023 at 6:30 p.m. (EEST) Inside information: Toivo Group Plc announces its intention to carry out a directed share issue of new shares NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Toivo Group Plc (“Toivo” or the “Company”) intends to carry out a directed share issue for an initial number of approximately

General meeting in Solstad Offshore ASA

Reference is made to the stock exchange announcement dated 7 December 2023 regarding a request from Kistefos AS (“Kistefos”) that the board of Solstad Offshore ASA (“SOFF”) convenes an extraordinary general meeting in SOFF. The date for the general meeting has been postponed in understanding with Kistefos. The date of the general meeting will be communicated separately later. Skudeneshavn, 18 December 2023 Contacts Lars Peder Solstad CEO, at +47 91 31 85 85 Kjetil Ramstad CFO, at +47 90 75 94 89 Solstad Offshore ASA www.solstad.com This information is subject of the

Transactions carried out under Kongsberg Automotive’s share buy-back program

As announced on November 7, 2023 Kongsberg Automotive ASA (KA) has put in place a non-discretionary agreement with Danske Bank for the repurchase of up to 2.5% of its outstanding shares in the market. The share repurchases started on November 17, 2023. Date Aggregated Daily Weighted Total Volume (# of Average Price Transaction Shares) (NOK) Value(NOK)December 12, 2023 300,000 1.94 582,480December 13, 2023 300,000 1.91 572,940December 14, 2023 300,000

Inside information, profit warning: Anora Group lowers its guidance for 2023

Anora Group Plc   Inside information   18 December 2023 at 6:00 p.m. EET Inside information, profit warning: Anora Group lowers its guidance for 2023 Anora Group lowers its guidance for 2023. Anora now expects the company’s comparable EBITDA for 2023 to be EUR 66-69 million. Previously Anora expected the comparable EBITDA to be EUR 70-78 million. For the full year 2022, Anora’s comparable EBITDA was EUR 76.1 million. The main reasons for lowering the guidance are weaker profitability of the Wine segment than previously forecasted as well as lower monopoly sales in the fourth

Director Change

EnQuest PLC 18 December 2023 Directorate Change EnQuest PLC ('EnQuest' or the 'Company') announces that Karina Litvack, Non-Executive Director, has informed the Board of her intention to resign as Non-Executive Director of the Company with immediate effect, due to an unexpected conflict arising through the EU Unbundling Directive which prohibits any director of a European power transmission company from also serving on the board of an upstream operator. Ms. Litvack is a director of Terna S.p.A, an Italian company. As part of its ongoing Board renewal process, the EnQuest PLC Board

Publication of a Prospectus

Regulatory Announcement Publication of Prospectus Not for release, publication or distribution, directly or indirectly, in or into the United States. The following prospectus has been approved by the Financial Conduct Authority and is available for viewing: 2[nd] Supplementary Notes Base Prospectus dated December 18, 2023 relating to the Programme for the Issuance of Securities of Royal Bank of Canada. The 2nd Supplementary Notes Base Prospectus, together with the documents incorporated by reference therein, have been submitted to the National Storage Mechanism and will

Publication of a Prospectus

Regulatory AnnouncementRoyal Bank of CanadaDecember 18, 2023Publication of ProspectusNot for release, publication or distribution, directly or indirectly, in or into the United States.The following prospectus has been approved by the Financial Conduct Authority and, along with the documents incorporated by reference therein, is available for viewing:2[nd] Supplementary Prospectus dated December 18, 2023 relating to the Programme for the €75,000,000,000 Global Covered Bond Programme of Royal Bank of Canada, unconditionally and irrevocably guaranteed as to payments by RBC Covered

EQT Private Equity to acquire Zeus, a global leader in advanced polymer components used in life-saving medical procedures

· EQT Private Equity to acquire Zeus, a leading supplier of custom polymer components to the world’s most innovative medical device and industrial companies · Transaction highlights EQT’s commitment to partnering with leading, purpose-driven companies that deliver inherently critical services to society. Zeus uses its material science expertise to develop advanced components for medical devices used in minimally invasive, life-saving procedures · EQT will support Zeus through investments in additional production capacity, R&D, and operational excellenceThe EQT X fund (“EQT”) and Zeus

Buy-back of shares in Hemnet during 11 - 15 December, 2023

Hemnet Group AB (publ) (LEI code: 5493008VIU67J3HUAR07) ("Hemnet") has during 11 to 15 December 2023 repurchased in total 37,000 own ordinary shares (ISIN code: SE0015671995) as part of the share buy-back program initiated by the board of directors of Hemnet in order to adjust Hemnet's capital structure.   The share buy-backs form part of the share buy-back program of maximum SEK 450,000,000 announced by Hemnet on 27 April 2023. The share buy-back program is being carried out in accordance with the EU Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated

Wetteri Oyj - Manager's Transactions - Päivi Simula

Wetteri Plc  18 December 2023 16.30 EETWetteri Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Päivi Simula Position: Closely associated person  (1):Person Discharging Managerial Responsibilities In Issuer Name: Aarne Simula Position: Chief Executive Officer Issuer: Wetteri Oyj LEI: 743700TDB62DGAFROB24 Notification type: INITIAL NOTIFICATION Reference number: 46399/6/6 ____________________________________________ Transaction date: 2023-12-14 Outside a trading venue

Wetteri Plc - Manager's Transactions - Simula Invest Oy

Wetteri Plc  Manager's Transactions 18 December 2023 16.30 EETWetteri Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Simula Invest Oy Position: Closely associated person (X) Legal person  (1):Person Discharging Managerial Responsibilities In Issuer Name: Aarne Simula Position: Chief Executive Officer Issuer: Wetteri Oyj LEI: 743700TDB62DGAFROB24 Notification type: INITIAL NOTIFICATION Reference number: 46402/6/6 ____________________________________________ Transaction date:

Notification in accordance with the Finnish Securities Market Act Chapter 9 § 5: BlackRock, Inc.’s holding in Wärtsilä Corporation

Wärtsilä Corporation, flagging notification, 18 December 2023 at 16:30 EETNotification in accordance with the Finnish Securities Market Act Chapter 9 § 5: BlackRock, Inc.’s holding in Wärtsilä CorporationBlackRock, Inc. has informed Wärtsilä Corporation that it has crossed below the 5% disclosure limit on total holding in shares and voting rights on 15 December 2023. Total position of BlackRock, Inc. and its funds subject to the notification: % of % of shares Total of Total number of shares shares and voting both in % and voting rights

Veidekke: Mandatory notification of trade

Mrs. Hanne Rønneberg, a board member and primary insider in Veidekke ASA, has today bought 1 000 Veidekke shares at a price of NOK 104 each. After this transaction Mrs. Hanne Rønneberg holds 2 700 shares in Veidekke. For further information, please see enclosure at www.newsweb.no. Ref.: Jørgen Wiese Porsmyr, CFO, +47 907 59 058, jorgen-wiese.porsmyr@veidekke.no This information is subject to disclosure requirements set out in the Market Abuse Regulation EU 596/2014 Article 19 and the Norwegian Securities Trading Act Section 5-12.

Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)

Stockholm, December 18, 2023: Immedica today announces that the European Commission has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. The approval follows the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on October 12. Anders Edvell, CEO of Immedica comments: “Today’s approval marks a major milestone for Immedica, but an even greater one for the people living with ARG1-D and

Approved autism study marks the start of the expansion into the Middle East

SensoDetect, Arabian Trade House (ATH) and Princess Nourah bint Abdulrahman University’s (PNU) Hospital, King Abdullah bin Abdulaziz University Hospital (KAAUH), Riyadh, Kingdom of Saudi Arabia have now agreed upon the terms of the previously announced autism study. The longitudinal study, “Early, objective detection of autism” is planned to start in January 2024 and will mark the start of the next major product launch for SensoDetect and its distributor ATH. A start that ATH projects will result in millions of measurements in the Middle east during the coming years.About Princess Nourah

Peptonic's patented intimate cleanser to be sold in 293 Apoteket stores

Peptonic Medical AB (publ) ("Peptonic") announced today that the company's patented intimate wash, VagiVital Moisturizing V Cleanser, is being offered for sale in 293 Apoteket stores in Sweden.”VagiVital Moisturizing V Cleanser is more than just an intimate wash as it also moisturizes, balances pH and does not disturb the delicate intimate microflora. It is very gratifying that Apoteket is recognizing this and now starts selling our preventive intimate wash in its physical stores. The agreement is yet another proof that our unique holistic concept of Diagnosing, Treating and Preventing

There are no items matching the current filter
There are no more items matching the current filter
Back to top